scispace - formally typeset
F

Frank C. Odds

Researcher at University of Aberdeen

Publications -  289
Citations -  32456

Frank C. Odds is an academic researcher from University of Aberdeen. The author has contributed to research in topics: Candida albicans & Corpus albicans. The author has an hindex of 82, co-authored 289 publications receiving 30707 citations. Previous affiliations of Frank C. Odds include University of Cincinnati Academic Health Center & Janssen Pharmaceutica.

Papers
More filters
Journal ArticleDOI

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

TL;DR: These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.
Journal ArticleDOI

Synergy, antagonism, and what the chequerboard puts between them

TL;DR: This document is intended to be used for educational purposes only and should not be relied on as a guide for making decisions about major decisions about copyrighted material.
Book

Candida and candidosis

Frank C. Odds
TL;DR: A comprehensive and critical review of the medical and scientific literature on Candida infections by a leading authority in the field.
Journal ArticleDOI

Antifungal agents: mechanisms of action

TL;DR: The sordarins represent a novel class of agents that inhibit fungal protein synthesis, and three are echinocandins, which inhibit synthesis of fungal cell wall polysaccharides--a new mode of action.
Journal ArticleDOI

Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections

TL;DR: The conceptual framework underlying interpretation of antimicrobial susceptibility testing results is examined and these ideas are used to drive analysis of data packages developed by the respective manufacturers that correlate fluconazole and itraconazole MICs with outcome of candidal infections.